Logo image of RCKT

ROCKET PHARMACEUTICALS INC (RCKT) Stock Fundamental Analysis

USA - NASDAQ:RCKT - US77313F1066 - Common Stock

3.929 USD
+0.22 (+5.9%)
Last: 10/20/2025, 11:49:52 AM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to RCKT. RCKT was compared to 534 industry peers in the Biotechnology industry. RCKT may be in some trouble as it scores bad on both profitability and health. RCKT has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year RCKT has reported negative net income.
RCKT had a negative operating cash flow in the past year.
In the past 5 years RCKT always reported negative net income.
In the past 5 years RCKT always reported negative operating cash flow.
RCKT Yearly Net Income VS EBIT VS OCF VS FCFRCKT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M -250M

1.2 Ratios

RCKT's Return On Assets of -61.19% is in line compared to the rest of the industry. RCKT outperforms 42.32% of its industry peers.
Looking at the Return On Equity, with a value of -72.72%, RCKT is in line with its industry, outperforming 55.24% of the companies in the same industry.
Industry RankSector Rank
ROA -61.19%
ROE -72.72%
ROIC N/A
ROA(3y)-44.2%
ROA(5y)-38.05%
ROE(3y)-50.34%
ROE(5y)-43.19%
ROIC(3y)N/A
ROIC(5y)N/A
RCKT Yearly ROA, ROE, ROICRCKT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

RCKT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RCKT Yearly Profit, Operating, Gross MarginsRCKT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

3

2. Health

2.1 Basic Checks

RCKT has more shares outstanding than it did 1 year ago.
RCKT has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, RCKT has a worse debt to assets ratio.
RCKT Yearly Shares OutstandingRCKT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
RCKT Yearly Total Debt VS Total AssetsRCKT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

Based on the Altman-Z score of -2.29, we must say that RCKT is in the distress zone and has some risk of bankruptcy.
RCKT has a Altman-Z score (-2.29) which is in line with its industry peers.
A Debt/Equity ratio of 0.05 indicates that RCKT is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.05, RCKT is doing worse than 61.05% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Altman-Z -2.29
ROIC/WACCN/A
WACCN/A
RCKT Yearly LT Debt VS Equity VS FCFRCKT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

A Current Ratio of 6.39 indicates that RCKT has no problem at all paying its short term obligations.
RCKT's Current ratio of 6.39 is fine compared to the rest of the industry. RCKT outperforms 66.29% of its industry peers.
RCKT has a Quick Ratio of 6.39. This indicates that RCKT is financially healthy and has no problem in meeting its short term obligations.
RCKT's Quick ratio of 6.39 is fine compared to the rest of the industry. RCKT outperforms 66.67% of its industry peers.
Industry RankSector Rank
Current Ratio 6.39
Quick Ratio 6.39
RCKT Yearly Current Assets VS Current LiabilitesRCKT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 11.11% over the past year.
EPS 1Y (TTM)11.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20.27%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, RCKT will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.89% on average per year.
The Revenue is expected to grow by 473.92% on average over the next years. This is a very strong growth
EPS Next Y21.59%
EPS Next 2Y18.57%
EPS Next 3Y13.52%
EPS Next 5Y11.89%
Revenue Next Year1817.18%
Revenue Next 2Y2560.76%
Revenue Next 3Y940.84%
Revenue Next 5Y473.92%

3.3 Evolution

RCKT Yearly Revenue VS EstimatesRCKT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
RCKT Yearly EPS VS EstimatesRCKT Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -2 -4 -6 -8 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RCKT. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RCKT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RCKT Price Earnings VS Forward Price EarningsRCKT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RCKT Per share dataRCKT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2 3

4.3 Compensation for Growth

RCKT's earnings are expected to grow with 13.52% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.57%
EPS Next 3Y13.52%

More info and screens

0

5. Dividend

5.1 Amount

RCKT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ROCKET PHARMACEUTICALS INC

NASDAQ:RCKT (10/20/2025, 11:49:52 AM)

3.929

+0.22 (+5.9%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-07 2025-08-07/amc
Earnings (Next)11-06 2025-11-06/amc
Inst Owners88.61%
Inst Owner Change0.05%
Ins Owners2.97%
Ins Owner Change29.8%
Market Cap423.94M
Analysts75.45
Price Target8.08 (105.65%)
Short Float %14.3%
Short Ratio3.93
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)3.33%
Min EPS beat(2)-3.91%
Max EPS beat(2)10.56%
EPS beat(4)3
Avg EPS beat(4)7.6%
Min EPS beat(4)-3.91%
Max EPS beat(4)15.34%
EPS beat(8)6
Avg EPS beat(8)7.93%
EPS beat(12)7
Avg EPS beat(12)4.77%
EPS beat(16)9
Avg EPS beat(16)1.82%
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)0
Avg Revenue beat(4)-100%
Min Revenue beat(4)-100%
Max Revenue beat(4)-100%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.08%
PT rev (3m)-13.75%
EPS NQ rev (1m)-2.35%
EPS NQ rev (3m)7.07%
EPS NY rev (1m)-0.6%
EPS NY rev (3m)5.42%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-14.89%
Revenue NY rev (1m)-96.28%
Revenue NY rev (3m)-95.79%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.2
P/tB 1.46
EV/EBITDA N/A
EPS(TTM)-2.48
EYN/A
EPS(NY)-1.62
Fwd EYN/A
FCF(TTM)-1.91
FCFYN/A
OCF(TTM)-1.89
OCFYN/A
SpS0
BVpS3.28
TBVpS2.69
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -61.19%
ROE -72.72%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-44.2%
ROA(5y)-38.05%
ROE(3y)-50.34%
ROE(5y)-43.19%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 22.36%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.39
Quick Ratio 6.39
Altman-Z -2.29
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)144.02%
Cap/Depr(5y)620.56%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)11.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20.27%
EPS Next Y21.59%
EPS Next 2Y18.57%
EPS Next 3Y13.52%
EPS Next 5Y11.89%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year1817.18%
Revenue Next 2Y2560.76%
Revenue Next 3Y940.84%
Revenue Next 5Y473.92%
EBIT growth 1Y1.65%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year22.71%
EBIT Next 3Y10.88%
EBIT Next 5YN/A
FCF growth 1Y6.14%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y2.32%
OCF growth 3YN/A
OCF growth 5YN/A